Neuroimaging Core

神经影像核心

• 批准号: 10628507
• 负责人: PETER Thornton FOX
• 金额: $ 93.83万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-15 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10628507
• 关键词: Age Years; Alzheimer' s Disease; Alzheimer' s disease related dementia; Anosmia; Archives; Biological Markers; Blood flow; Brain; COVID-19; COVID-19 survivors; COVID-19 test; Clinical; Communities; Data; Data Analyses; Dementia; Disease; Electronic Health Record; Enrollment; Evaluation; Excision; Functional Magnetic Resonance Imaging; Genetic; Genetic Variation; Image; Impaired cognition; Incidence; Individual; Infection; Liquid substance; Longevity; Magnetic Resonance Imaging; Medial; Meta-Analysis; Metabolic syndrome; Morphologic artifacts; Motion; Neuronal Dysfunction; Participant; Pathway interactions; Patients; Phase; Polymerase Chain Reaction; Population; Post-Acute Sequelae of SARS-CoV-2 Infection; Process; Prospective, cohort study; Protocols documentation; Quality Control; Recording of previous events; Research; Risk; Risk Factors; Running; SARS-CoV-2 infection; SARS-CoV-2 positive; Sampling; Serum; Severities; Site; Smoking; South Texas; Structure; Surface; Survivors; System; Temporal Lobe; Testing; Visual; Woman; analysis pipeline; apolipoprotein E-4; archive data; arm; biobank; blood oxygen level dependent; cohort; comorbidity; data acquisition; data archive; data exploration; data management; data sharing; data standards; dementia risk; expectation; experience; follow-up; glucose metabolism; human old age (65+); image archival system; indexing; interest; men; neuroimaging; pandemic disease; recruit; statistics

The ISAVRAD U19 proposes a five-site, two-arm (patients and controls), longitudinal (3 assessments/subject) study enrolling 4,300 individuals. All 5 enrollment sites are experienced in recruiting genetically homogenous cohorts. Pilot data of various types are provided in the respective projects and cores. Participants will be men and women (~50:50 ratio) who are > 60 years of age and either have a history of polymerase chain reaction (PCR) test positive COVID-19 infection (75% of sample) or have no history of COVID-19 (25% of sample). Evaluations will be performed upon enrollment, 18 months, and 36 months. Evaluations will comprise a standardized data acquisition battery including assessment of clinical status and serum sampling for fluid-based biomarkers and genetics. Neuroimaging will be conducted at enrollment and at 18 months. Data acquisition, preprocessing, archiving and sharing – both within the U19 and with the scientific community at large – will be overseen by the Administrative, Clinical, Neuroimaging, and Data Management & Statistics Cores of the U19. The Neuroimaging Core will manage neuroimaging acquisition (2 assessments/subject), quality control, harmonization, data archiving and data sharing at all five study sites. Image acquisition, quality control and harmonization strategies will emulate those of ADNI3 and Mark VCID supplemented by team expertise. Minimal data preprocessing will use pipelined approaches both volumetric and surface-based. Surface-based analyses will emulate Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) protocols, with the expectation that other large studies of the post-acute sequelae of COVID-19 (PASC) will emerge and that ENIGMA community will embrace the challenge of ongoing data exploration both meta-analytic and mega- analytic. Aim 1: Image Acquisition, Harmonization and Quality Control. Structural MRI and functional MRI images will be acquired at all five study sites. Structural MRI acquisitions will emulate those of ADNI3, UKBioBank, Lifespan HCP, MarkVCID and GOBS. Functional MRI acquisitions will emulate the latest GOBS. The Neuroimaging Core will coordinate acquisition across sites, including harmonization and quality control. Aim 2: Image Preprocessing and Pipeline analytics. The Neuroimaging Core will perform post-acquisition quality control, image preprocessing (artifact removal, motion correction, etc.), and run widely used volumetric and surface-based pipeline analyses. Blood-oxygen-level-dependent (BOLD)-based indices of neuronal dysfunction will be cross validated with glucose metabolism and blood flow. Aim 3: Image Archiving, Access Control, and Sharing. Anonymized raw and processed volumetric and surfaced- based images and image-derived data (region of interest [ROI] values) and visual-inspection scores will be archived in the XNAT system. Spreadsheet-compatible data will be provided to the Data Management and Statistics Core.

Isavrad U19提案提出了五个站点，两臂（患者和对照组），纵向（3个评估/受试者） 研究招募4300个人。所有5个注册地点均在招募遗传同质性方面经历 同伙。各种项目和核心提供了各种类型的试点数据。参与者将是男人 女性（约50：50）年龄较高60岁，有聚合酶链反应的史 （PCR）测试COVID阳性-19阳性感染（占样品的75％）或没有Covid-19的史（样品的25％）。 评估将在入学期间，18个月和36个月进行。评估将完成 标准化数据采集电池，包括评估基于流体的临床状态和血清抽样 生物标志物和遗传学。神经影像学会将在入学时和18个月进行。数据获取， 在U19内以及整个科学界的预处理，存档和共享 - 将是 由U19的行政，临床，神经影像和数据管理与统计核心监督。 神经影像核心将管理神经影像学的习得（2个评估/受试者），质量控制， 在所有五个研究站点上的协调，数据归档和数据共享。图像获取，质量控制和 协调策略将模仿ADNI3和Mark VCID，并补充了团队专业知识。最小 数据预处理将使用管道的方法和基于表面的方法。基于表面的分析 将通过荟萃分析（Enigma）方案模仿增强的神经成像遗传学，并使用 期望其他大型研究COVID-19（PASC）的急性后遗症将出现，并且 Onigma社区将面临正在进行的数据探索元分析和巨型的挑战 分析。 目标1：图像获取，协调和质量控制。结构性MRI和功能性MRI图像将是 在所有五个研究地点获得。结构性MRI获取将模仿ADNI3，UKBIOBANK，LISESPAN HCP，MarkvCID和GOB。功能性MRI采集将模仿最新的GOB。神经成像核心 将协调跨站点的采集，包括协调和质量控制。 目标2：图像预处理和管道分析。神经影像学核心将执行后期质量 控制，图像预处理（伪影去除，运动校正等），并运行广泛使用的体积和 基于表面的管道分析。神经元功能障碍的基于血氧级依赖性（粗体）指标 将通过葡萄糖代谢和血流进行交叉验证。 AIM 3：图像归档，访问控制和共享。匿名的原始和处理的体积和浮出水面 - 基于图像和图像衍生的数据（感兴趣的区域[ROI]值）和视觉检查分数将为 存档在XNAT系统中。电子表格兼容的数据将提供给数据管理和 统计核心。